Related Experiment Video
Updated: Aug 24, 2025
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Eribulin in Patients with Liposarcoma and Leiomyosarcoma: A Retrospective Single-Center Experience
Oskar Steinbrecher1, Thomas Brodowicz1, Markus Raderer1
1Clinical Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.
Introduction:
Soft tissue sarcomas are rare and heterogenous malignancies with a poor prognosis in advanced disease stages. Eribulin is used in metastatic liposarcoma (LPS) patients, who have failed first-line chemotherapy and has been approved for use in patients with LPS in the USA and Europe due to its efficacy in this histological subtype in a phase 3 trial. We have evaluated efficacy and tolerability of eribulin in LPS and leiomyosarcoma (LMS) patients in the routine clinical setting at our department.
Methods:
In this retrospective single-center analysis, efficacy and safety of eribulin were retrospectively evaluated in advanced LPS and LMS patients at the Division of Oncology, Medical University of Vienna.
Results:
A total of 32 adult patients treated with eribulin were identified and included in this analysis. Overall response rate was 9.4% for all patients, with one patient with LPS and two patients with LMS showing a partial response. Disease control rate (partial response plus stable disease) for all patients was 50% (LPS: 47.1%; LMS 53.3%). No statistically significant difference in median progression-free survival and overall survival was detected between patients with LPS and LMS (p = 0.807 and p = 0.519, respectively). Patients with LMS (n = 2) had received fewer previous therapy lines than patients with LPS (n = 14) (≤ previous treatment lines, p < 0.001). Toxicity was generally manageable, and grade 3 + 4 events were rare.
Conclusion:
The activity and tolerability of eribulin in LPS as in well in LMS patients in the routine clinical setting is comparable to outcomes reported in published phase 3 trials.
Insights
Eribulin demonstrated comparable efficacy and tolerability in routine clinical settings for advanced liposarcoma (LPS) and leiomyosarcoma (LMS) patients, mirroring phase 3 trial outcomes.
Area of Science:
- Oncology
- Pharmacology
Background:
- Soft tissue sarcomas, including liposarcoma (LPS) and leiomyosarcoma (LMS), are rare and aggressive cancers.
- Eribulin is an approved treatment for metastatic LPS after first-line chemotherapy failure.
Purpose of the Study:
- To evaluate the efficacy and tolerability of eribulin in LPS and LMS patients in a real-world clinical setting.
- To compare outcomes between LPS and LMS patients treated with eribulin.
Main Methods:
- Retrospective single-center analysis of 32 advanced LPS and LMS patients treated with eribulin.
- Assessment of overall response rate, disease control rate, progression-free survival, overall survival, and toxicity.
Main Results:
- Overall response rate was 9.4%; disease control rate was 50% (LPS: 47.1%; LMS: 53.3%).
- No significant differences in progression-free or overall survival between LPS and LMS patients.
- Toxicity was manageable with rare severe (grade 3+) events.
Conclusions:
- Eribulin shows comparable activity and tolerability in routine clinical practice for LPS and LMS patients.
- Real-world data support the use of eribulin in these advanced sarcoma subtypes.
